| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac2c17e532220d91aca9a28ef60f178b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-58 |
| filingDate |
1999-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44606d08c65b9d90cd1d683a3ff82a42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7426d774a39489fb4d8b89eb58bb1381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53c344249c7be0257680ed79569414c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1967d33782ff79c89a99f1beee5fb0cc |
| publicationDate |
2003-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-292849-B6 |
| titleOfInvention |
A controlled release formulation of oxycodone |
| abstract |
Oxycodone controlled release pharmaceutical composition for oral administration comprising a) an oxycodone salt equivalent to 10 to 160 mg oxycodone hydrochloride and b) a controlled release matrix different from an acrylic resin matrix to provide dissolution independently of pH and c) the formulation provides a maximum plasma oxycodone concentration of between 6 and 240 ng / ml at 2 to 4.5 hours after oral administration and a minimum plasma oxycodone concentration of 3 to 120 ng / ml at 10 to 14 hours when administered every 12 hours. hours after dosing |
| priorityDate |
1991-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |